Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 11/20 | 0.51 |
| ▸ | PPARA | Q07869 | 11/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5225370 | 0.94 | PPARG (0.52) | PPARGPPARAMAPTCYP2C9KCNH2 | |
| SCHEMBL5228366 | 0.92 | PPARG (0.51) | PPARGPPARAMAPTCYP2C9KCNH2 | |
| SCHEMBL5226750 | 0.92 | PPARG (0.58) | PPARGPPARACYP2C9KCNH2 | |
| SCHEMBL5224964 | 0.85 | PPARG (0.59) | PPARGPPARAMAPTCYP2C9KCNH2 | |
| SCHEMBL5227032 | 0.85 | PPARA (0.54) | PPARGPPARACYP2C9KCNH2 | |
| SCHEMBL5223943 | 0.84 | PPARG (0.58) | PPARGPPARAMAPTCYP2C9KCNH2 | |
| SCHEMBL5230649 | 0.79 | PPARA (0.55) | PPARGPPARACYP2C9KCNH2 | |
| SCHEMBL5441640 | 0.79 | MAPT (0.48) | PPARGPPARAMAPTCYP2C9KCNH2 | |
| SCHEMBL5231076 | 0.78 | PPARG (0.60) | PPARGPPARACYP2C9KCNH2 | |
| SCHEMBL5434355 | 0.78 | PPARG (0.48) | PPARGPPARAMAPTCYP2C9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254882-A1 | Sulfamide Derivatives and Pharmaceutical Composition for Upregulation of Lipid Metabolism Comprising Same | CRYSTAL GENOMICS, INC. (KR) | 2007-11-01 | — | — | US | disclosed |
| EP-1778654-A1 | SULFAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR UPREGULATION OF LIPID METABOLISM COMPRISING SAME | Crystalgenomics, Inc. (KR) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006006832-A1 | SULFAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR UPREGULATION OF LIPID METABOLISM COMPRISING SAME | CRYSTALGENOMICS, INC. (KR) | 2006-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254882-A1 | Sulfamide Derivatives and Pharmaceutical Composition for Upregulation of Lipid Metabolism Comprising Same | SULT2A1, SPTLC2, SGMS2 | PPARG 399/4885PPARA 190/4885MAPT 3705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.